Comparative efficacy of topically applied flurbiprofen, diclofenac, tolmetin, and suprofen for the treatment of experimentally induced blood-aqueous barrier disruption in dogs

American Journal of Veterinary Research

Volumn 57, Issue 6, 1996, Pages 875-878

  Ward, Daniel A ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FLURBIPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; SUPROFEN; TOLMETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ARTICLE; BLOOD EYE BARRIER; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG THERAPY; NONHUMAN; PARACENTESIS; TOPICAL DRUG ADMINISTRATION;

ANIMALS; ANTERIOR CHAMBER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-AQUEOUS BARRIER; DICLOFENAC; DOGS; EYE; FLUORESCEIN; FLUORESCEINS; FLUOROPHOTOMETRY; FLURBIPROFEN; OCULAR PHYSIOLOGY; OPHTHALMIC SOLUTIONS; RANDOM ALLOCATION; SUPROFEN; TOLMETIN;

EID: 0029992730     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Wood DC, Contaxis I, Sweet D, et al. Response of rabbits to corticosteroids. I. Influence on growth, intraocular pressure and lens transparency. Am J Ophthalmol 1967;63:841-849.
2. Goldmann H. Cortisone glaucoma. Arch Ophthalmol 1962; 68:621-626.
3. Petroutsos G, Guimaraes R, Giraud JP, et al. Corticosleroids and corneal epithelial wound healing. Br J Ophthalmol 1982; 66:705-708.
4. Brown SI, Weller CA, Vidrich AM. Effect of corticosteroids on corneal collagenase of rabbits. Am J Ophthalmol 1970;70:744-747.
5. Stern GA, Okumoto M, Friedlaender M, et al. The effect of combined gentamicin-corticosteroid treatment on gentamicin-resistant Pseudomonas keratitis. Ann Ophthalmol 1980;12:1011-1014.
6. O'Day DM, Ray WA, Robinson R, et al. Efficacy of antifungal agents in the cornea. II. Influence of corticosteroids. Invest Ophthalmol Vis Sci 1984;25:331-335.
7. Mitsui Y, Hanabusa J. Corneal infections after cortisone therapy. Br J Ophthalmol 1955;39:244-250.
8. Martin CL. Effect of topical vitamin A, antibiotic, mineral oil, and subconjunctival corticosteroid on corneal epithelial wound healing in the dog. J Am Vet Med Assoc 1971;159:1392-1399.
9. Whitley RD. Canine cornea. In: Gelatt KN, ed. Veterinary ophthalmology. 2nd ed. Philadelphia: Lea & Febiger, 1991;307-356.
10. Slatter D. Cornea and sciera. In: Slatter D, ed. Fundamentals of veterinary ophthalmology. 2nd ed. Philadelphia. WB Saunders Co, 1990;257-303.
11. Nasisse MP. Canine ulcerative keratitis. Compend Contin Educ Pract Vet 1985;7:686-701.
12. Heinrichs DA, Leith AB. Effect of flurbiprofen on the maintenance of pupillary dilation during cataract surgery. Can J Ophthalmol 1990;25:239-242.
13. Diestelhorst M, Aspacher F, Konen W, et al. The effect of flurbiprofen 0.03% eye drops on the blood aqueous barrier in extracapsular cataract extraction with IOL implantation. Int Ophthalmol 1991;15:69-73.
14. Chaudhary KP, Sofat BK. Preoperative topical flurbiprofen-Na+ in extracapsular lens extraction role in maintaining intraoperative pupillary dilatation. Indian J Ophthalmol 1992;40:109-114.
15. Kraff MC, Sanders DR, McGuigan L, et al. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluorophotometric study. Arch Ophthalmol 1990;108:380-383.
16. Herbort CP, Mermoud A, Schnyder C, et al. Anti-inflammatory effect of diclofenac drops after argon laser trabeculoplasty. Arch Ophthalmol 1993;111:481-483.
17. Ronen S, Rozenman Y, Zylbermann R, et al. Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery. Ann Ophthalmol 1985;17:577-581.
18. Stark WJ, Fagadau WR, Stewart RH, et al. Reduction of pupillary constriction during cataract surgery using suprofen. Arch Ophthalmol 1986;104:364-366.
19. Leibowitz HM, Ryan WJ, Kupferman A, et al. Bioavailability and corneal ami-inflammatory effect of topical suprofen. Invest Ophthalmol Vis Sci 1986;27:628-631.
20. Flach AJ, Jaffe NS, Akers WA. The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone. Ann Ophthalmol 1989;21: 407-411.
21. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 1988;95:1279-1284.
22. Flach AJ, Graham J, Kruger LP, et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution. A double-masked, paired comparison with vehicle-placebo solution study. Arch Ophthalmol 1988;106:344-347.
23. Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophthalmol 1984;16:1116-1121.
24. Smerdon DL, Hung SO, Akingbehin T Double-blind controlled trial to compare anti-inflammatory effects of tolmetin 2%, prednisolone 0.5%, and placebo in post-cataract extraction eyes. Br J Ophthalmol 1986;70:761-763.
25. Abelson MB, Butrus SI, Kliman GH, et al. Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol 1987;3:63-75.
26. Kulkarni P, Srinivasan BD. Diclofenac and enolicam as ocular anti-inflammatory drugs in rabbit corneal wound model. J Ocul Pharmacol 1986;2:171-175.
27. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974;26:33-67.
28. Ward DA, Ferguson DC, Kaswan RL, et al. Fluorophotometric evaluation of experimental blood-aqueous barrier disruption in dogs. Am J Vet Res 1991;52:1433-1437.
29. Sanders DR, Spigelman A, Kraft C, et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier. Arch Ophthalmol 1983;101:131-133.
30. Sanders DR, Kraff MC, Leiberman HL, et al. Breakdown and reestablishment of blood-aqueous barrier with implant surgery. Arch Ophthalmol 1981;100:588-590.
31. Whiteclocke RAF, Eakins KE. Vascular changes in the anterior uvea of the rabbit produced by prostaglandins. Arch Ophthalmol 1973;89:495-499.
32. Vander JF, Greven CM, Maguire JI, et al. Flurbiprofen sodium to prevent intraoperative miosis during vitreoretinal surgery. Am J Ophthalmol 1989;108:288-291.
33. Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery. Ann Ophthalmol 1984;16:919-921.
34. Bonomi L, Perfetti S, Bellucci R, et al. Prevention of surgically induced miosis by diclofenac eye drops. Ann Ophthalmol 1987;19:142-145.
35. Ferguson VM, Spalton DJ. Recovery of the blood-aqueous barrier after cataract surgery. Br J Ophthalmol 1991;75:106-110.
36. Sachdev MS, Mehta MR, Dada VK, et al. Pupillary dilatation during cataract surgery - relative efficacy of indomethacin and flurbiprofen. Ophthalmic Surg 1990;21:557-559.
37. Zimm JL, Holmes JM, Anderson C, et al. Effects of topical suprofen and flurbiprofen on the miosis produced by anterior chamber irrigation with cholinergic agonists. J Cataract Refract Surg 1991; 17:790-793.
38. Dimitrakos SA, Topouzidis C, Panidou Kynakidou I. Prevention of preoperative miosis: comparison between prostaglandin inhibitors. Sodium diclofenac and indomethacin in local application. J Fr Ophtalmol 1992;15:5-8.
39. Strobel J, Seitz W, Tietze K. Quantitative studies of protein and cell concentrations in the anterior chamber in cataract surgery with therapy using steroidal and non-steroidal antiphlogistic drugs. Ophthalmologica 1991;202:86-93.
40. Tilden ME, Boney RS, Goldenberg MM, et al. The effects of topical S(+)-ibuprofen on interleukin-1 induced ocular inflammation in a rabbit model. J Ocul Pharmacol 1990;6:131-135.
41. Psilas K, Kalogeropoulos C, Loucatzicos E, et al. The effect of indomethacin, diclofenac and flurbiprofen on the maintenance of mydriasis during extracapsular cataract extraction. Doc Ophthalmol 1992;81:293-300.
42. Podos SM, Becker B. Comparison of ocular prostaglandin synthesis inhibitors. Invest Ophthalmol 1976;15:841-844.
43. Trousdale MD, Barlow WE, McGuigan LJ. Assessment of diclofenac on herpes keratitis in rabbit eyes. Arch Ophthalmol 1989; 107:1664-1666.
44. Tsuchisaka H, Takase M. Topical flurbiprofen in intraocular surgery on diabetic and nondiabetic patients. Ann Ophthalmol 1990;22:15-23.
45. van Haeringen NJ, Glasius E, Oosterhuis JA, et al. Drug prevention of blood-aqueous barrier disruption. Ophthalmic Res 1983;15:180-184.
46. Lewis AJ, Furst DE. Introduction. In: Lewis AJ, Furst DE, eds. Nonsteroidal antiinflammatory drugs, mechanisms and clinical use. New York: Marcel Dekker, 1987;1-5.
47. Smith RJ, Lomen PL, Kaiser DG. Flurbiprofen. In: Lewis AJ, Furst DE, eds. Nonsteroidal antiinflammatory drugs, mechanisms and clinical use. New York: Marcel Dekker, 1987;393-418.
48. Liauw L, Moscaritola JD, Burcher J. Diclofenac. In: Lewis AJ, Furst DE, eds. Nonsteroidal antiinflammatory drugs, mechanisms and clinical use. New York: Marcel Dekker, 1987;329-347.
49. Glenn EM, Rohloff N, Bowman BJ, et al. The pharmacology of 2-(2-fluoro-4-biphenylyl) propionic acid (flurbiprofen). A potent non-steroidal anti-inflammatory drug. Agents Actions 1973;3:210-216.
50. Menasse R, Hedwall PR, Kraetz J, et al. Pharmacological properties of diclofenac sodium and its metabolites. J Rheumatol [Suppl] 1978;22:5-16.
51. Capetola RJ, Tolman EL, Argentieri DC, et al. Suprofen. In: Lewis AJ, Furst DE, eds. Nonsteroidal antiinflammatory drugs, mechanisms and clinical use. New York: Marcel Dekker, 1987;509-530.
52. Unger WG. Mediation of ocular response to injury and irritation: peptides versus prostaglandins. In: Bito LZ, Stjernschantz J, eds. The ocular effects of prostaglandins and other eicosanoids. New York: Alan R Liss, 1989;293-328.
53. Bartels SP, Pederson JE, Gaasterland DE, et al. Site of breakdown of the blood-aqueous barrier after paracentesis in the rhesus monkey eye. Invest Ophthalmol Vis Sci 1979;18:1050-1060.
54. Ward DA, Ferguson DC, Kaswan RL, et al. Leukotrienes and sensory innervation in blood-aqueous barrier disruption in the dog. J Ocul Pharmacol 1992;8:69-76.